Effectiveness of pharmaceutical care for improving medication-related quality of life and adherence to treatment among people living with schizophrenia: a randomised controlled trial

IF 1 Q4 PHARMACOLOGY & PHARMACY

Journal of Pharmacy Practice and Research Pub Date : 2024-02-13 DOI:10.1002/jppr.1909

Tatta Sriboonruang PhD, Wasanan Phonphairin MSc (Pharm), Siripan Phattanarudee PhD, Sirichai Chusiri PharmD, BCP

{"title":"Effectiveness of pharmaceutical care for improving medication-related quality of life and adherence to treatment among people living with schizophrenia: a randomised controlled trial","authors":"Tatta Sriboonruang PhD, Wasanan Phonphairin MSc (Pharm), Siripan Phattanarudee PhD, Sirichai Chusiri PharmD, BCP","doi":"10.1002/jppr.1909","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>People living with schizophrenia frequently exhibit poor medication adherence because of adverse drug reactions (ADRs) or lack of disease awareness. This prospective randomised controlled trial investigated the benefits of pharmaceutical care delivered by hospital pharmacists for improving pharmacotherapy-related quality of life and medication adherence among this patient group.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>The purpose of this study was to evaluate the effectiveness of pharmaceutical care interventions in enhancing medication adherence and improving the quality of life of people living with schizophrenia.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>Data were collected during inpatient and subsequent outpatient treatment from 6 January–8 June 2021. Participants were divided into two groups via block randomisation: a control group receiving standard treatment; and an intervention group receiving pharmaceutical care combined with standard treatment. The pharmaceutical care comprised medication review, monitoring of drug-related problems (including ADRs), adjustment of the dose of antipsychotic medicines in collaboration with psychiatrists, and counselling of participants and caregivers about disease management before discharge. Pharmacotherapy-related quality of life was assessed using the short version of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL), whereas medication adherence was evaluated using the Medication Taking Behaviour in Thai Patients (MTB-Thai). The primary outcomes were the average change in the PROMPT-QoL score from inpatient to outpatient care and the average outpatient MTB-Thai score. Ethical approval was granted by the Srithanya Hospital Office of the Ethics Commission for Human Research (Reference no: STY.COA008/2564) and the study conforms to the Declaration of Helsinki. Informed consent was obtained from all patient and caregiver participants via a project information sheet and the completion of a written consent form.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>At the end of the study, compared with the control group, the intervention group exhibited a significantly lower ADR prevalence (57.90% vs 79.70%, p < 0.05) and a greater change in the mean PROMPT-QoL scores pertaining to ‘obtaining information of medicines and diseases’, ‘impact of medicine side effects’, ‘ease of use of medicines’, and ‘therapeutic relationship’. In addition, the intervention group achieved a significantly higher mean of medicine adherence score than the control group (22.81 ± 1.61 vs 16.85 ± 3.00, p < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Pharmaceutical care may improve the outcomes of people living with schizophrenia by improving their quality of life, decreasing ADRs, and enhancing medication adherence.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 3","pages":"217-227"},"PeriodicalIF":1.0000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

People living with schizophrenia frequently exhibit poor medication adherence because of adverse drug reactions (ADRs) or lack of disease awareness. This prospective randomised controlled trial investigated the benefits of pharmaceutical care delivered by hospital pharmacists for improving pharmacotherapy-related quality of life and medication adherence among this patient group.

Aim

The purpose of this study was to evaluate the effectiveness of pharmaceutical care interventions in enhancing medication adherence and improving the quality of life of people living with schizophrenia.

Method

Data were collected during inpatient and subsequent outpatient treatment from 6 January–8 June 2021. Participants were divided into two groups via block randomisation: a control group receiving standard treatment; and an intervention group receiving pharmaceutical care combined with standard treatment. The pharmaceutical care comprised medication review, monitoring of drug-related problems (including ADRs), adjustment of the dose of antipsychotic medicines in collaboration with psychiatrists, and counselling of participants and caregivers about disease management before discharge. Pharmacotherapy-related quality of life was assessed using the short version of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL), whereas medication adherence was evaluated using the Medication Taking Behaviour in Thai Patients (MTB-Thai). The primary outcomes were the average change in the PROMPT-QoL score from inpatient to outpatient care and the average outpatient MTB-Thai score. Ethical approval was granted by the Srithanya Hospital Office of the Ethics Commission for Human Research (Reference no: STY.COA008/2564) and the study conforms to the Declaration of Helsinki. Informed consent was obtained from all patient and caregiver participants via a project information sheet and the completion of a written consent form.

Results

At the end of the study, compared with the control group, the intervention group exhibited a significantly lower ADR prevalence (57.90% vs 79.70%, p < 0.05) and a greater change in the mean PROMPT-QoL scores pertaining to ‘obtaining information of medicines and diseases’, ‘impact of medicine side effects’, ‘ease of use of medicines’, and ‘therapeutic relationship’. In addition, the intervention group achieved a significantly higher mean of medicine adherence score than the control group (22.81 ± 1.61 vs 16.85 ± 3.00, p < 0.001).

Conclusion

Pharmaceutical care may improve the outcomes of people living with schizophrenia by improving their quality of life, decreasing ADRs, and enhancing medication adherence.

查看原文本刊更多论文

药物护理对改善精神分裂症患者与药物相关的生活质量和坚持治疗的效果：随机对照试验

精神分裂症患者常常因为药物不良反应（ADR）或缺乏疾病意识而导致服药依从性差。这项前瞻性随机对照试验调查了医院药剂师提供的药物护理对改善该患者群体药物治疗相关生活质量和服药依从性的益处。这项研究的目的是评估药物护理干预对提高精神分裂症患者服药依从性和改善其生活质量的效果。通过整群随机法将参与者分为两组：对照组接受标准治疗；干预组在接受标准治疗的同时接受药物护理。药物护理包括药物复查、监测药物相关问题（包括不良反应）、与精神科医生合作调整抗精神病药物的剂量，以及在出院前为参与者和护理人员提供有关疾病管理的咨询服务。与药物治疗相关的生活质量采用患者报告的药物治疗生活质量结果测量（PROMPT-QoL）简易版进行评估，而药物治疗依从性则采用泰国患者服药行为（MTB-Thai）进行评估。主要结果为从住院病人到门诊病人的 PROMPT-QoL 平均得分变化和门诊病人 MTB-Thai 平均得分变化。该研究已获得 Srithanya 医院人类研究伦理委员会办公室的伦理批准（编号：Sty.COA008/2564），并符合《赫尔辛基宣言》。在研究结束时，与对照组相比，干预组的 ADR 发生率明显降低（57.90% vs 79.70%，P < 0.05），PROMPT-QoL 在 "获取药物和疾病信息"、"药物副作用的影响"、"药物的易用性 "和 "治疗关系 "方面的平均得分也有较大变化。此外，干预组的服药依从性平均得分明显高于对照组（22.81 ± 1.61 vs 16.85 ± 3.00，P < 0.001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmacy Practice and Research Health Professions-Pharmacy

CiteScore

1.60

自引率

9.50%

发文量

期刊介绍： The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.